Eleven families,
and the evidence is not evenly spread.

Grouped by mechanism,
not by marketed benefit.

Compounds sit in a family because of how they are proposed to act, not because of what they are sold for. Reading a family as a set is the fastest way to see where the evidence in a category actually sits — and the bar on each row is that family’s own grade distribution, not a score.

• ATissue repair and cytoprotectionOne compound carries a real randomised programme. The rest is animal work and pairings never tested as pairings.8 guides · 178 peer-reviewed sources
• BGrowth hormone axis, GHRH analoguesFour compounds, one receptor, and four completely different evidence positions.4 guides · 87 peer-reviewed sources
• CGrowth hormone axis, ghrelin receptor agonistsThe most trial-bearing family in the library — and the clearest demonstration that trials can be run and still fail.6 guides · 112 peer-reviewed sources
• DGrowth factors and myostatin inhibitorsThe only family in which not one compound has a published human study of any kind.5 guides · 92 peer-reviewed sources
• ELongevity, mitochondrial and senolytic compoundsEvery grade in the system is represented here, and four of these compounds have never been given to a person.11 guides · 244 peer-reviewed sources
• FCognitive and neuroactive peptidesA retracted mechanism, a structure disputed in its own literature, and two compounds with no studies at all.8 guides · 155 peer-reviewed sources
• GImmune peptidesThe largest randomised trial in this family was negative, and it was not close.4 guides · 76 peer-reviewed sources
• HMelanocortin peptidesThree marketing authorisations, three narrow indications, and one unlicensed compound on the same receptors.4 guides · 80 peer-reviewed sources
• IReproductive, endocrine and sleep peptidesThe newest human sleep evidence in this family is more than thirty years old.4 guides · 81 peer-reviewed sources
• JCosmetic and topical peptidesFour ingredients in thousands of consumer products, and no randomised trial between them.4 guides · 34 peer-reviewed sources
• KMetabolic and GLP-1 compoundsThe widest evidence gap in the library, running between compounds that are routinely discussed together.10 guides · 193 peer-reviewed sources